仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain （TIGIT）. Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab （HY-P9904）, may be effective against multiple solid malignancies-most notably non-small cell lung cancer （NSCLC）